Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
Datopotamab deruxtecan application in the EU for patients with advanced nonsquamous non-small cell lung cancer voluntarily withdrawn
Tuesday, December 24, 2024AstraZeneca and Daiichi Sankyo have voluntarily withdrawn the marketing authorisation application MAA in the EU for datopotamab deruxtecan DatoDXd for the treatment of adult patients with locally advanced or metastatic nonsquamous
Sanofi Launches Phase III Program for its VPC21 Vaccine and Expands Collaboration with SK Bioscience to Develop Next-Generation Pneumococcal Conjugate Vaccines
Tuesday, December 24, 2024Sanofi and SK Bioscience are entering a new chapter in their collaboration in the field of pneumococcal vaccines and are expanding it to include the development approval and commercialization of a new generation of PCVs for children and adults reaffi...
Tagrisso approved in the EU for patients with unresectable EGFR-mutated lung cancer
Monday, December 23, 2024AstraZenecas Tagrisso osimertinib has been approved in the European Union EU for the treatment of adult patients with locally advanced unresectable nonsmall cell lung cancer NSCLC whose tumours have epidermal growth factor receptor
Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VGT-1849A, a Novel and Selective Antisense Oligonucleotide Candidate for the Treatment of Polycythemia Vera
Saturday, December 21, 2024Vanda Pharmaceuticals Inctoday announced the US Food and Drug Administration FDA has granted Orphan Drug Designation for VGTA a selective antisense oligonucleotide ASObased JAK inhibitor for the treatment of polycythemia vera PV a form of a rare hema...
FDA approves Zepbound® (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity
Saturday, December 21, 2024Eli Lilly and Companytoday announced the US Food and Drug Administration FDA approved Zepbound tirzepatide as the first and only prescription medicine for adults with moderatetosevere obstructive sleep apnea OSA and obesity
U.S. Food and Drug Administration issues Complete Response Letter for the glepaglutide New Drug Application for the treatment of short bowel syndrome
Friday, December 20, 2024Zealand Pharma AS a biotechnology company focused on the discovery and development of innovative peptidebased medicines today announced that the US Food and Drug Administration FDA has issued a Complete Response Letter CRL for the companys New Drug A...
Quoin Pharmaceuticals Announces FDA Clearance to Initiate New QRX003 Netherton Syndrome Clinical Study
Friday, December 20, 2024Quoin Pharmaceuticals Ltd a clinical stage specialty pharmaceutical company focused on rare and orphan diseases today announces FDA clearance to initiate a new additional Netherton Syndrome NS clinical study for QRX QRX is a topical lotion that conta...
Immunovia CEO and board members announce intention to fully exercise their TO2 warrants
Thursday, December 19, 2024Immunovia the pancreatic cancer diagnostics company today announced its CEO and board members intend to exercise all TO warrants they received in the companys rights issue that was announced on May Immunovia CEO Jeff Borcherding one of the companys...
Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome
Thursday, December 19, 2024Praxis Precision Medicines Inc a clinicalstage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system CNS disorders characterized by neuronal excitationinhibition imbalance today announced...
Lilly's Kisunla™ (donanemab-azbt) Approved in China for the Treatment of Early Symptomatic Alzheimer's Disease
Wednesday, December 18, 2024Eli Lilly and Company today announced that the National Medical Products Administration NMPA in China has approved Kisunla donanemabazbt mg mL every four weeks injection for IV infusion Eli Lilly and Companys Alzheimers treatment for adults with ear...
